114 related articles for article (PubMed ID: 38602409)
1. Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Guo L; Tian F; Liu L; Chen M; Jiang C; Li S; Liu C; Zhang Y; Qin J; Yu D; Zong Y; Dai W
Diabetes Obes Metab; 2024 Jul; 26(7):2830-2838. PubMed ID: 38602409
[TBL] [Abstract][Full Text] [Related]
2. Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Wang Y; Jiang C; Dong X; Chen M; Gu Q; Zhang L; Fu Y; Pan T; Bi Y; Song W; Xu J; Lu W; Sun X; Ye Z; Zhang D; Peng L; Lin X; Dai W; Wang Q; Yang W
Diabetes Obes Metab; 2024 Jul; 26(7):2774-2786. PubMed ID: 38618970
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Gao L; Cheng Z; Su B; Su X; Song W; Guo Y; Liao L; Chen X; Li J; Tan X; Xu F; Pang S; Wang K; Ye J; Wang Y; Chen L; Sun J; Ji L
Diabetes Obes Metab; 2023 Mar; 25(3):785-795. PubMed ID: 36433709
[TBL] [Abstract][Full Text] [Related]
5. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Weng J; Zeng L; Zhang Y; Qu S; Wang X; Li P; Fu L; Ma B; Ye S; Sun J; Lu W; Liu Z; Chen D; Cheng Z; Liu H; Zhang T; Zou J
Diabetes Obes Metab; 2021 Aug; 23(8):1754-1764. PubMed ID: 33769656
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Owens DR; Swallow R; Dugi KA; Woerle HJ
Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study.
Ji L; Li L; Ma J; Li X; Li D; Meng B; Lu W; Sun J; Liu Y; Takayanagi G; Wang Y
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00222. PubMed ID: 33855222
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
Wang W; Yang J; Yang G; Gong Y; Patel S; Zhang C; Izumoto T; Ning G
J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS
Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
18. Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
Chen Y; Liu X; Li Q; Ma J; Lv X; Guo L; Wang C; Shi Y; Li Y; Johnsson E; Wang M; Zhao J; Ji L
Diabetes Obes Metab; 2018 Apr; 20(4):1044-1049. PubMed ID: 29144061
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
Kim MK; Rhee EJ; Han KA; Woo AC; Lee MK; Ku BJ; Chung CH; Kim KA; Lee HW; Park IB; Park JY; Chul Jang HC; Park KS; Jang WI; Cha BY
Diabetes Obes Metab; 2015 Mar; 17(3):309-12. PubMed ID: 25475929
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial.
Xu J; Ling H; Geng J; ; Huang Y; Xie Y; Zheng H; Niu H; Zhang T; Yuan J; Xiao X
Diabetes Obes Metab; 2022 Nov; 24(11):2232-2240. PubMed ID: 35791646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
